Xiao-Yi Xiao

Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA.

Miikana Therapeutics, Inc. develops therapeutics for the treatment of cancer and inflammatory diseases. It is a biopharmaceutical company focused on development and discovery of novel oncology drugs. It also performs its own research and licenses other companies. The company was founded in 2002 by Tak Mak, Dinesh Patel and S. Gail Eckhardt and is headquartered in Fremont, CA.

Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA

Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.

Discovery Partners International, Inc. (DPI) used to research laboratory looking to discovery pharmaceutical products. It was a small molecule and natural product based drug discovery company that offered collaborations and services complementing the internal capabilities of pharmaceutical and biopharmaceutical. Discovery Partners has actively contributed to dozens of drug discovery collaborations. The company had operations in United States and Europe. The company was founded in 1995 was headquartered in San Diego, CA